FDA orders NAION warnings for GLP-1 drugs
The FDA requires GLP-1 drugs to include warnings about a rare risk of NAION, a condition that can cause sudden permanent vision loss; reporting names Ozempic, Wegovy, Mounjaro, Zepbound and Soliqua.
Source: The Guardian ↗AI-assisted summary & Christian commentary